Publications list

Genetic diseases

Polycystic kidney disease

1. Devuyst O, Persu A, Stoenoiu MS, Pirson Y, Lens XM, Chauveau D: Enos polymorphism and renal disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 41:1125, 2003

2. Gogusev J, Murakami I, Doussau M, Telvi L, Stojkoski A, Lesavre P, Droz D: Molecular cytogenetic aberrations in autosomal dominant polycystic kidney disease tissue. J Am Soc Nephrol 14:359-366, 2003

3. Joly D, Hummel A, Ruello A, Knebelmann B: Ciliary function of polycystins: a new model for cystogenesis. Nephrol Dial Transplant 18:1689-1692, 2003

4. Joly D, Morel V, Hummel A, Ruello A, Nusbaum P, Patey N, Noel LH, Rousselle P, Knebelmann B: Beta4 integrin and laminin 5 are aberrantly expressed in polycystic kidney disease: role in increased cell adhesion and migration. Am J Pathol 163:1791-1800, 2003

5. Persu A, El-Khattabi O, Messiaen T, Pirson Y, Chauveau D, Devuyst O: Influence of ACE (I/D) and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2032-2038, 2003

6. Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong AC, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC: Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 361:2196-2201, 2003

7. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lens XM, Devuyst O: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11:229-241, 2002

8. Pirson Y, Chauveau D, Torres V: Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13:269-276, 2002

9. Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE, Harris PC: A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int 61:1588-1599, 2002

10. Fonck C, Chauveau D, Gagnadoux MF, Pirson Y, Grünfeld JP: Autosomal recessive polycystic kidney disease in adulthood. Nephrol Dial Transplant 16:1648-1652, 2001

11. Chauveau D, Fakhouri F, Grünfeld JP: Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 11:1767-1775, 2000

Alport syndrome

1. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC: X-linked alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14:2603-2610, 2003

2. Basile C, Schiavone P, Heidet L, Grünfeld JP: Hereditary nephritis with macrothrombocytopenia: phenotypic variety and the genotypic defect. J Nephrol 15:320-323, 2002

3. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grünfeld JP, Germain DP: Arterial remodelling in Fabry disease. Acta Paediatr Suppl 91:62-66, 2002

4. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grünfeld JP, Germain DP: Non-invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet 38:629-631, 2001

5. Knebelmann B, Fakhouri F, Grünfeld JP: Hereditary nephritis with macrothrombocytopenia: no longer an Alport syndrome variant. Nephrol Dial Transplant 16:1101-1103, 2001

6. Grünfeld JP: Contemporary diagnostic approach in Alport's syndrome. Ren Fail 22:759-763, 2000

7. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC: X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649-657, 2000

8. Noel LH: Renal pathology and ultrastructural findings in Alport's syndrome. Ren Fail 22:751-758, 2000

von Hippel-Lindau disease, cancer

1. Richard S, Croisille L, Yvart J, Casadeval N, Eschwege P, Aghakhani N, David P, Gaudric A, Scigalla P, Hermine O: Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 99:3851-3853, 2002

2. Karumanchi SA, Jiang L, Knebelmann B, Stuart-Tilley AK, Alper SL, Sukhatme VP: VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol Genomics 5:119-128, 2001

3. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O'Toole D, Bernades P, Ruszniewski P, Richard S: Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 119:1087-1095, 2000

4. Paraf F, Chauveau D, Chretien Y, Richard S, Grünfeld JP, Droz D: Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology 36:457-465, 2000

Fabry disease

1. De Schoenmakere G, Chauveau D, Grünfeld JP: Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33-35, 2003

2. Grünfeld JP: How to improve the early diagnosis of Fabry's disease? Kidney Int 64:1136-1137, 2003

3. Grünfeld JP, Chauveau D, Levy M: Anderson-Fabry disease: its place among other genetic causes of renal disease. J Am Soc Nephrol 13 Suppl 2:S126-129, 2002

4. Grünfeld JP, Lidove O, Barbey F: Heterozygotes with Fabry's disease. Contrib Nephrol :208-210, 2001

5. Grünfeld JP, Lidove O, Joly D, Barbey F: Renal disease in Fabry patients. J Inherit Metab Dis 24 Suppl 2:71-74; discussion 65, 2001

Other genetic diseases

1. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM, Viron B, Jacquot C, Gagnadoux MF, Chauveau D, Buchler M, Cochat P, Cosyns JP, Mougenot B, Rider MH, Antignac C, Verellen-Dumoulin C, Pirson Y: A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 14:2883-2893, 2003

2. Grünfeld JP: Ethics in renal genetics. Nefrologia 23 Suppl 1:11-13, 2003

3. Guery B, Choukroun G, Noel LH, Clavel P, Rotig A, Lebon S, Rustin P, Bellane-Chantelot C, Mougenot B, Grünfeld JP, Chauveau D: The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol 14:2099-2108, 2003

4. Tricot L, Yahiaoui Y, Teixeira L, Benabdallah L, Rothschild E, Juquel JP, Satre V, Grünfeld JP, Chauveau D: End-stage renal failure in Lowe syndrome. Nephrol Dial Transplant 18:1923-1925, 2003

5. Arrondel C, Vodovar N, Knebelmann B, Grünfeld JP, Gubler MC, Antignac C, Heidet L: Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 13:65-74, 2002

6. Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, Bircan Z, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroes H, Li Volti G, Mir S, Mocan H, Nayir A, Ozen S, Rodriguez Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE: Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet 39:796-803, 2002

7. Disse-Nicodeme S, Achard JM, Potier J, Delahousse M, Fiquet-Kempf B, Stern N, Blanchard A, Guilbaud JC, Niaudet P, Chauveau D, Dussol B, Berland Y, Dequiedt P, Ader JL, Paillard M, Grünfeld JP, Fournier A, Corvol P, Jeunemaitre X: Familial hyperkalemic hypertension (Gordon syndrome): evidence for phenotypic variability in a study of 7 families. Adv Nephrol Necker Hosp 31:55-68, 2001

8. Sternberg D, Maisonobe T, Jurkat-Rott K, Nicole S, Launay E, Chauveau D, Tabti N, Lehmann-Horn F, Hainque B, Fontaine B: Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 124:1091-1099, 2001

9. Amiel J, Audollent S, Joly D, Dureau P, Salomon R, Tellier AL, Auge J, Bouissou F, Antignac C, Gubler MC, Eccles MR, Munnich A, Vekemans M, Lyonnet S, Attie-Bitach T: PAX2 mutations in renal-coloboma syndrome: mutational hotspot and germline mosaicism. Eur J Hum Genet 8:820-826, 2000

10. Jurkat-Rott K, Mitrovic N, Hang C, Kouzmekine A, Iaizzo P, Herzog J, Lerche H, Nicole S, Vale-Santos J, Chauveau D, Fontaine B, Lehmann-Horn F: Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A 97:9549-9554, 2000

Systemic diseases, inflammation

Glomerular diseases

1. Fakhouri F, Teixeira L, Delarue R, Grünfeld JP: Rituximab for relapsing TTP/HUS., 2004 (in press). Annals of Internal Medicine 54:(in press), 2004

2. Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grünfeld JP, Niaudet P: Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550-557, 2003

3. Fakhouri F, Noel LH, Zuber J, Beaufils H, Martinez F, Lebon P, Papo T, Chauveau D, Bletry O, Grünfeld JP, Piette JC, Lesavre P: The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 41:1205-1211, 2003

4. Inal JM, Pascual M, Lesavre P, Schifferli JA: Complement inhibition in renal diseases. Nephrol Dial Transplant 18:237-240, 2003

5. Lobato L, Beirao I, Silva M, Bravo F, Silvestre F, Guimaraes S, Sousa A, Noel LH, Sequeiros J: Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant 18:532-538, 2003

6. Fakhouri F, Darre S, Droz D, Lemaire M, Nabarra B, Machet MC, Chauveau D, Lesavre P, Grünfeld JP, Noel LH, Knebelmann B: Mesangial IgG glomerulonephritis: a distinct type of primary glomerulonephritis. J Am Soc Nephrol 13:379-387, 2002

7. Fremeaux-Bacchi V, Noel LH, Schifferli JA: No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol Dial Transplant 17:2041-2043, 2002

8. Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P: SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis 40:1179-1184, 2002

9. Karras A, Noel LH, Droz D, Delansorne D, Saint-Andre JP, Aucouturier P, Alyanakian MA, Grünfeld JP, Lesavre P: Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 40:1091-1096, 2002

10. Nochy D, Daugas E, Hill G, Grünfeld JP: Antiphospholipid syndrome nephropathy. J Nephrol 15:446-461, 2002

11. Fakhouri F, Robino C, Lemaire M, Droz D, Noel LH, Knebelmann B, Lesavre P: Granulomatous renal disease in a patient with common variable immunodeficiency. Am J Kidney Dis 38:E7, 2001

12. Chauveau D, Joly D, Grünfeld JP: Retroperitoneal fibrosis of unknown origin. Nephrol Dial Transplant 15:1100, 2000

13. Droz D, Nochy D, Noel LH, Heudes D, Nabarra B, Hill GS: Thrombotic microangiopathies: renal and extrarenal lesions. Adv Nephrol Necker Hosp 30:235-259, 2000

14. Fakhouri F, Vincent F, Legendre C: Therapeutic plasma exchange. Ann Intern Med 132:760-761, 2000

15. Fakhouri F, Vincent F, Legendre C: Pathological and therapeutic distinctions in HUS/TTP. Lancet 355:497; author reply 497-498, 2000

16. Hafdi Z, Lesavre P, Nejjari M, Halbwachs-Mecarelli L, Droz D, Noel LH: Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein--IAP (CD47) in human glomerular diseases. Cell Adhes Commun 7:441-451, 2000

17. Herody M, Duvic C, Noel LH, Nedelec G, Grünfeld JP: Cigarette smoking and other inhaled toxins in anti-GBM disease. Contrib Nephrol 130:94-102, 2000

18. Rieu P, Noel LH, Droz D, Beaufils H, Gessain A, Hermine O, Lesavre P: Glomerular involvement in lymphoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS). Adv Nephrol Necker Hosp 30:305-331, 2000

Vasculitis

1. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (Lesavre P, membre du steering commitee): A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44, 2003

2. Hauer HA, Bajema IM, Hagen EC, Noel LH, Ferrario F, Waldherr R, van Houwelingen HC, Lesavre P, Sinico RA, van der Woude F, Gaskin G, Verburgh CA, de Heer E, Bruijn JA: Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant 17:587-596, 2002

3. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC: Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62:1732-1742, 2002

4. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC: Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61:80-89, 2002

5. Le Hello C, Bonte I, Mora JJ, Verneuil L, Noel LH, Guillevin L: Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil. Rheumatology (Oxford) 41:236-237, 2002

6. de Groot K, Adu D, Savage CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018-2027, 2001

7. Girard T, Mahr A, Noel LH, Cordier JF, Lesavre P, Andre MH, Guillevin L: Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 40:147-151, 2001

8. Jayne D: Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13:48-55, 2001

9. Mouly S, Brillet G, Stern M, Lesavre P, Guillevin L: Pulmonary giant bulla in Wegener's granulomatosis. Scand J Rheumatol 29:333-335, 2000

 

Classification of lupus glomerulonephritis (WHO/ISN/RPS)

1. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521-530, 2004

2. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241-250, 2004

Neutrophils and renal diseases

1. Durant S, Pederzoli M, Lepelletier Y, Canteloup S, Nusbaum P, Lesavre P, Witko-Sarsat V: Apoptosis-induced proteinase 3 membrane expression is independent from degranulation. J Leukoc Biol 75:87-98, 2004

2. Dehghani Zadeh A, Seveau S, Halbwachs-Mecarelli L, Keller HU: Chemotactically-induced redistribution of CD43 as related to polarity and locomotion of human polymorphonuclear leucocytes. Biol Cell 95:265-273, 2003

3. Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C: The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 193:1035-1044, 2001

4. Halbwachs-Mecarelli L, Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P: Neutrophil biology in relation to renal diseases. Adv Nephrol Necker Hosp 31:153-171, 2001

5. Hafdi Z, Lesavre P, Nejjari M, Halbwachs-Mecarelli L, Droz D, Noel LH: Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein--IAP (CD47) in human glomerular diseases. Cell Adhes Commun 7:441-451, 2000

6. Seveau S, Keller H, Maxfield FR, Piller F, Halbwachs-Mecarelli L: Neutrophil polarity and locomotion are associated with surface redistribution of leukosialin (CD43), an antiadhesive membrane molecule. Blood 95:2462-2470, 2000

7. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L: Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 80:617-653, 2000

Oxidative stress

1. Vicca S, Massy ZA, Hennequin C, Rihane D, Drueke TB, Lacour B: Apoptotic pathways involved in U937 cells exposed to LDL oxidized by hypochlorous acid. Free Radic Biol Med 35: 603-15, 2003

2. Witko-Sarsat V, Gausson V, Descamps-Latscha B: Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl :S11-14, 2003

3. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drüeke T, Santangelo F, Descamps-Latscha B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 64:82-91, 2003

4. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 20:481-484, 2002

5. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002

6. Descamps-Latscha B, Drüeke T, Witko-Sarsat V: Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 14:193-199, 2001

7. Descamps-Latscha B, Witko-Sarsat V: Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 78:S108-113, 2001

8. Drüeke TB, Khoa TN, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B: Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl 78:S114-119, 2001

9. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drüeke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001

Chronic renal failure and dialysis

Calcium & phosphate metabolism

1. Block GA, Martin KJ, deFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: The calcimimetic cincalcet (AMG 073) for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med 350: 1516-25, 2004

2. Drueke TB, Moe SM: Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment. Nephrol Dial Transplant 19: 534-6, 2004

3. Drüeke TB: Calcimimetics versus Vitamin D: What Are Their Relative Roles? Blood Purif 22:38-43, 2004

4. Moe SM, Drueke TB: A bridge to improving healthcare outcomes and quality of life. Am J Kidney Dis 43: 552-7, 2004

5. Angulo J, Nguyen-Khoa T, Massy ZA, Drueke TB, Serra J: Morphologic quantification of aortic calcification from low magnification images. Image Anal Stereol 22: 81-89, 2003

6. Drueke TB, McCarron DA: Paricalcitol as compared with calcitriol in patients undergoing hemodialysis (Editorial). N Engl J Med 349: 496-9, 2003

7. Moe SM, Drueke TB: Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23: 369-79, 2003

8. Drüeke TB, Eckardt KU: Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 17 Suppl 5:28-31, 2002

9. Drüeke TB: Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrol Dial Transplant 17 Suppl 11:20-22, 2002

10. Drüeke TB, Massy ZA: Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 20:494-497, 2002

11. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Urena P, Chaganti RS, Arnold A: Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 13:1490-1498, 2002

12. Locatelli F, Cannata-Andia JB, Drüeke TB, Horl WH, Fouque D, Heimburger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723-731, 2002

13. Drüeke TB: Genetic aspects of secondary hyperparathyroidism in uremia. Am J Kidney Dis 38:S143-146, 2001

14. Drüeke TB: Control of secondary hyperparathyroidism by vitamin D derivatives. Am J Kidney Dis 37:S58-61, 2001

15. Drüeke TB: The place of calcium and calcimimetics in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant 16 Suppl 6:15-17, 2001

16. Drüeke TB: Parathyroid gland hyperplasia in uremia. Kidney Int 59:1182-1183, 2001

17. Roussanne MC, Lieberherr M, Souberbielle JC, Sarfati E, Drüeke T, Bourdeau A: Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur J Clin Invest 31:610-616, 2001

18. Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Urena P, Chaganti RS, Pike JW, Arnold A: Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab 85:868-872, 2000

19. Cattan P, Halimi B, Aidan K, Billotey C, Tamas C, Drüeke TB, Sarfati E: Reoperation for secondary uremic hyperparathyroidism: are technical difficulties influenced by initial surgical procedure? Surgery 127:562-565, 2000

20. Drüeke TB: Renal osteodystrophy: management of hyperphosphataemia. Nephrol Dial Transplant 15 Suppl 5:32-33, 2000

21. Drüeke TB, Touam M, Thornley-Brown D, Rostand SG: Extraskeletal calcification in patients with chronic kidney failure. Adv Nephrol Necker Hosp 30:333-356, 2000

22. Drüeke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 11:1141-1152, 2000

23. Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Leger A, Lopez J, Acuna G, Petraglia A, Alvarez A, Caorsi H, Drüeke T, Ambrosoni P: [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations. Nephrol Dial Transplant 15:1201-1206, 2000

24. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Drüeke TB: Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 57:437-445, 2000

25. Hory BG, Roussanne MC, Rostand S, Bourdeau A, Drüeke TB, Gogusev J: Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture. J Endocrinol Invest 23:273-279, 2000

Disease progression, vascular disease, anemia and other

1. Massy ZA, Fumeron C, Borderie D, Tuppin P, Nguyen-Khoa T, Benoit MO, Jacquot C, Buisson C, Drueke TB, Ekindjian OG, Lacour B, Iliou MC: Increased pasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective study. J Am Soc Nephrol 15: 470-6, 2004

2. Touam M, Guery B, Goupy C, Menoyo V, Drueke T: Hypothyroidism and resistance to human recombinant erythropoietin. Nephrol Dial Transplant 19: 1020-1, 2004

3. Joly D, Anglicheau D, Alberti C, Nguyen AT, Touam M, Grünfeld JP, Jungers P: Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. J Am Soc Nephrol 14:1012-1021, 2003

4. Jungers PY, Nguyen-Khoa T, Joly D, Choukroun G, Massy ZA, Jungers P: Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage. Presse Med 32:212-216, 2003

5. Keane WF, Brenner BM, de Zeeuw D, Grünfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507, 2003

6. Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant 18: 153-7, 2003

7. Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, Mignon F, Grünfeld JP: Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 64:585-592, 2003

8. Vicca S, Massy ZA, Hennequin C, Rihane D, Nguyen-Khoa T, Drueke TB, Lacour B: New insights into the effects of the protein moiety of oxidized LDL (oxLDL). Kidney Int Suppl 125-7, 2003

9. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002

10. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, Drüeke T, Massy ZA: Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 17:865-870, 2002

11. Drüeke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 Suppl 7:25-28, 2001

12. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, Touam M, Nguyen AT, Grünfeld JP: Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 16:2357-2364, 2001

13. Muntzel MS, Malena H, Drüeke T: Inhibition of nitric oxide synthesis attenuates insulin-mediated sympathetic activation in rats. J Hypertens 19:1625-1631, 2001

14. Brenner BM, Cooper ME, Zeeuw Dd D, Grünfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simps R, Shahinar S: The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1:328-335, 2000

15. Drüeke TB: Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 15 Suppl 1:17-24, 2000

16. Jungers P, Khoa TN, Joly D, Choukroun G, Witko-Sarsat V, Massy ZA: Atherosclerotic complications in chronic renal failure: epidemiology and predictive factors. Adv Nephrol Necker Hosp 30:177-199, 2000